TotalMarketCap

Virax Biolabs Group

VRAXNasdaq United KingdomHealth CareBiotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$1.567 M

$1.17 -2.92%

Close of 6 Nov 2026

As of 6 Nov 2026, Virax Biolabs Group (VRAX) has a market capitalization of $1.57M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

579,218

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →
  1. #15VolitionrxVNRX$5.84M
  2. #16Cardio DiagnosticsCDIO$5.16M
  3. #17Trinity BiotechTRIB$4.79M
  4. #18Q/C TechnologiesQCLS$2.71M
  5. #19Virax Biolabs GroupVRAX$1.57M

What if Virax Biolabs Group were worth as much as…

Open the what-if tool →

Gold $28.2T

$20,994,146

Per share 18,020,726× higher

Bitcoin $1.53T

$1,135,957

Per share 975,070× higher

Apple $5.02T

$3,729,240

Per share 3,201,064× higher

Or at a round number

$2.00M$5.00M$10.0M$20.0M

Where these numbers come from

Share counts and financials for Virax Biolabs Group are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.